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a b s t r a c t
Malaria parasites are frequently polymorphic at the antigenic targets of many candidate vaccines, pre-
sumably as a consequence of selection pressure fromprotective immune responses. Conventionalwisdom
is therefore that vaccines directed against a single variant could select for non-target variants, rendering
the vaccine useless. Many people have argued that a solution is to develop vaccines containing the prod-
ucts of more than one variant of the target. However, we are unaware of any evidence that multi-allele
vaccines better protect hosts against parasites or morbidity. Moreover, selection of antigen-variants is not
the only evolution that could occur in response to vaccination. Increased virulence could also be favored
if more aggressive strains are less well controlled by vaccine-induced immunity. Virulence and antigenic
identity have been confounded in all studies so far, and so we do not know formally from any animal
or human studies whether vaccine failure has been due to evasion of protective responses by variants at
target epitopes, or whether vaccines are just less good at protecting against more aggressive strains.
Using the rodent malaria model Plasmodium chabaudi and recombinant apical membrane antigen-1
(AMA-1), we tested whether a bi-allelic vaccine afforded greater protection from parasite infection and
morbidity than did vaccination with the component alleles alone. We also tested the effect of mono-
and bi-allelic vaccination on within-host selection of mixed P. chabaudi infections, and whether parasite
virulence mediates pathogen titres in immunized hosts. We found that vaccination with the bi-allelic
AMA-1 formulationdidnot afford thehost greater protection fromparasite infection ormorbidity thandid
mono-allelic AMA-1 immunization. Mono-allelic immunization increased the frequency of heterologous
clones in mixed clone infections. There was no evidence that any type of immunization regime favored
virulence. A single AMA-1 variant is a component of candidate malaria vaccines current in human trials;
our results suggest that adding extra AMA-1 alleles to these vaccines would not confer clinical beneﬁts,
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. Introduction
Malaria parasite antigens which are the targets of protective
mmune responses are frequently polymorphic, with antigen-
oding genes having multiple allelic forms [1]. Polymorphisms
ikely arise as a consequence of immune-mediated selection
ecause host responses can be more effective against parasites of
he immunising strain than against different strains (strain-speciﬁc
mmunity) [2–6]. Sequence polymorphisms have been directly
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mplicated in antigenic escape [7–9], and inmalaria endemic areas,
mmunity is acquired slowly, probably because repeated exposure
s required to generate an effective response against a repertoire
f strains [10–12]. The existence of antigenic polymorphism is
herefore of considerable concern to malaria vaccine developers
ecause it implies that single antigen vaccines will have trou-
le inducing protective immunity against polymorphic targets
13–16].
One approach to minimizing vaccine-induced strain-speciﬁcity
as been to design vaccines which combine more than one allele of
Open access under CC BY license.nantigen [1,17–19].However, the inclusionofmore thanoneallelic
orm of an antigen may not be sufﬁcient to overcome substantial
olymorphisms [9], and there is little experimental evidence that
ulti-allele vaccines actually afford the host more protection from
orbidity than do single antigen vaccines.
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Furthermore, selection of antigen-variants is not the only evo-
ution that could occur in response to widespread vaccination.
heoretically, vaccination has the potential to cause evolution-
ry change in parasite virulence (parasite-induced host damage)
y altering the way natural selection acts on parasite popula-
ions [20–27]. In experimental evolution experiments, the rodent
alaria Plasmodium chabaudi became virulent more rapidly if
erially passaged through mice previously immunized with live
arasites [28]. The most likely explanation for this is that more
ggressive variants are less well controlled by immunity.
To date, we still do not fully understand how vaccines will
lter gene frequencies in malaria parasite populations. Evidence
or selection in the ﬁeld comes from a small phase 1-2b trial of
he “Combination B” blood-stage malaria vaccine [29]. This vaccine
ontained a single antigen from each of three polymorphic loci of
. falciparum. One of these loci, merozoite surface protein-2 (MSP-
), is dimorphic, with each parasite having an allele from one of
wo allelic families (labelled 3D7 and FC27). TheMSP-2 allele in the
ombination B vaccine came from the 3D7 family. Among parasites
ubsequently acquired by vaccines, 3D7-type alleles were rarer
han in people given a placebo. Vaccination thus selected against
he variant contained in the vaccine. Interestingly, the FC27 allelic
amily is associated with more virulent infections [30]. Therefore,
t is not clear whether the vaccine-imposed selection was due to
mmune speciﬁcity [15,31] or whether the vaccine was less good at
ontrolling more virulent infections.
Many candidate vaccines against malaria are directed against
he asexual blood stage, with the principal target being the mero-
oite. Apical merozoite antigen-1 (AMA-1) is a promising vaccine
andidate as it possesses fewer polymorphisms than other mero-
oite antigens [2,13]. AMA-1 is thought to play a major role
uring erythrocyte re-modelling and invasion [32]. Immuniza-
ion with AMA-1 confers protection against parasite challenge
n a number of animal models, probably by inducing antibod-
es which inhibit invasion [2,7,33–36]. Furthermore, humans and
ther species immunized with single allele AMA-1 vaccines raise
ntibodies which inhibit erythrocyte invasion in vitro [13,37]. In
ndemic populations, naturally acquired antibody to P. falciparum
MA-1 (PfAMA-1) is associated with protection from falciparum
alaria [38–42]. At least six different vaccines based on the AMA-
allele from the P. falciparum 3D7 strain are currently in efﬁcacy
rials in humans [43–45].
However, there are more than 60 polymorphic sites in the AMA-
protein, and most of these are non-randomly dispersed point
utations on domain I [46–50]. These point mutations may be
f immunological importance. Protection in mice is strain-speciﬁc,
nd growth and invasion inhibition assays (GIA) and ELISA show
hat antibodies from animals and human ﬁeld sera inhibit growth
n a strain-speciﬁc manner [2,13,34,38,43,47]. Allelic replacement
xperiments have directly implicated sequence polymorphism in
ntigenic escape [7], and cross-strain inhibition assays suggest that
he extent of escape correlates with sequence distance between
he vaccine and the target strain [8]. In an attempt to overcome
train-speciﬁcity, vaccine researchers are beginning to combine
llelic variants of AMA-1. For example, one group immunized rhe-
us monkeys with a mixture of two allelic forms of PfAMA-1
designated AMA-1-C1) or the component alleles and measured
esponses in vitro using GIA and ELISA [8,51,52]. The resulting anti-
odieswere similarly effective regardlessofwhether immunization
as with a single variant or AMA-1-C1. Another group immunized
ice and rabbits with two allelic variants of domain I and II of
MA-1 ectodomain from P. falciparum isolates. The anti-AMA-1
ntibodies obtained with both proteins were active in an in vitro
arasite growth invasion/inhibition assay, but to no greater extent
han with either of the variants alone [53]. Together these results
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ave raised questions about the necessity of using multi-allele vac-
ines.
Here we use the rodent malaria P. chabaudi and two alleles of
he blood-stage malaria vaccine candidate AMA-1 to investigate (i)
hether immunization with a single or bi-allelic AMA-1 variant
ormulation afforded the host the greatest protection from mor-
idity and parasite infection, (ii) how these different vaccination
egimes can alter clonal frequencies in mixed infections, and (iii)
hether more virulent clones are better at evading heterologous
accine-induced protective responses.
. Materials and methods
.1. Parasites and hosts
P. chabaudi adami clones were originally derived from wild-
aught thicket rats (Thamnomys rutilans) in the Congo and stored
s frozen stabilites in liquid nitrogen with subscript codes used to
dentify their position in clonal history [54,55]. In this experiment
e used clones DS500 and DK122 originally cloned from isolates
08XZ and556KA, respectively. The nucleotide sequences of theDK
ndDS P. chabaudiAMA-1 (PcAMA-1) gene differ at 79 sites [34,56].
osts were inbred female C57BL/6 mice aged 6–8 weeks (Harlan,
ngland) maintained as described previously [57]. Studies by oth-
rs [34] and our ownpilot studies showed that these clones differ in
irulence during the infection of C57BL/6 female mice, with clone
S generating substantially more parasites and inducing greater
eight and red blood cell loss relative to DK.
.2. Immunizations and isotype ELISA
Here we used an immunization protocol adapted from Anders
t al. [2]. Prior to immunization, mice were randomized into four
roups of eighteen (Table 1). Immunization was with the highly
mmunogenic ectodomian of the full AMA-1 protein termed AMA-
B. For mono-allelic immunizations (hereafter referred to as DS
MA-1 or DK AMA-1), groups of mice were injected intraperi-
oneally with 10g of the appropriate protein emulsiﬁed in 100l
f the adjuvant Montanide ISA720 (Seppic, France). For bi-allelic
mmunizations, mice were injected with a mixture of 5g of both
S and DK AMA-1, giving the same total dose of antigen as for
he single antigen immunizations, again emulsiﬁed in Montanide
SA720. Control mice were injected with 100l emulsion of PBS in
ontanide ISA720. Mice were given a single booster immunization
ith the same amount of antigen emulsiﬁed in Montanide ISA720
weeks after the primary immunization.
To ensure that antigen immunization successfully generated
ntibody responses, and to determine whether there was any
ross-reactivity between the antibodies generated to the differ-
nt immunizing antigens, we ﬁrst carried out a pilot experiment.
total of 11 mice were immunized with DS AMA-1, 11 with DK
MA-1, and 10 were sham-immunized. We estimated the quan-
ity of IgG2b antigen-speciﬁc antibodies in all mice sera 11 days
fter the booster immunization by ELISA using wells coated with
S AMA-1 or DK AMA-1. Thus the sera from 32 mice were tested in
4wells.Weused IgG2b as previouswork in our laboratory showed
hat C57BL/6 produce this isotype in response to P. chabaudi infec-
ion (K. Grocock, A. Graham, unpublished). Protection induced by
mmunization with recombinant AMA-1 is isotype independent
58b]. Given the lack of cross-reactivity we observed in this pilot
xperiment (see Section 3), in the main experiment, we measured
gG2b isotype antibodies to each antigen separately only from the
era of mice immunized with a mixture of DS and DK AMA-1 and
n sham-immunized control mice.
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Table 1
Experimental design
Number of mice per immunization Infecting clone Number of mice per parasite infection Number of deaths Number of euthanized
Sham-immun
18
DS 6 3 2
Sham-immun DK 6
Sham-immun DS+DK 6
DK AMA-1
18
DS 6
DK AMA-1 DK 6
DK AMA-1 DS+DK 6
DS AMA-1
18
DS 6 1
DS AMA-1 DK 6
DSAMA-1 DS+DK 6 1
Bi-allelic
18
DS 6 2 1
Bi-allelic DK 6
Bi-allelic DS+DK 6
Total 72 72 7 3
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immunization was either with DK AMA-1, DS AMA-1, a formulation containing a
‘sham-immunization’). Groups of 18 mice were immunized with one of the four tr
K alone, clone DS alone or a mixture of both. During the experiment 7 mice were
redetermined levels of morbidity prescribed by animal care protocols.
In both the pilot and main experiments, sera fractions were
eparated by centrifugation from 20l of blood taken from a tail
nip and were stored at −80 ◦C. High binding 96 well ELISA Max-
sorb immunoplates (Nunc) were coated with either DS AMA-1
r DK AMA-1 at a concentration of 1g/ml in 0.06M carbonate
uffer (0.04M NaHCO3, 0.02M NaCO3, pH 9.6) in a ﬁnal volume of
0l perwell. Plateswere stored at 4 ◦Covernight to allow the anti-
en to bind. Non-speciﬁc binding was blocked by incubating wells
ith 5% BSA: carbonate buffer (200l per well) for 2h at 37 ◦C.
ells were then washed three times in Tris buffered saline with
.01% Tween 20 (TBST). We used end-point dilution methods to
etect IgG2b titres: serum samples were detected in a serial dilu-
ion 1/100-1/204800 using TBST as a diluent, in a ﬁnal volume of
0l per well and incubated for 2h at 37 ◦C. Wells were washed
hree times in TBST. HRP conjugated goat anti-mouse IgG2b detec-
ion antibody (Southern Biotech 1100-05) was diluted 1/4000 in
BST to a ﬁnal volume of 50l per well. Plates were incubated for
h at 37 ◦C. Wells were washed three times in TBST followed by
ﬁnal wash in distilled water. ABTS peroxide substrate (Insight
iotechnology)wasaddedat100l perwell andallowed todevelop
t room temperature for 20min. Optical densitywas read at 405nm
sing a spectrophotometer. IgG2b isotype antibody titres were cal-
ulated as the reciprocal of the greatest dilution at which optical
ensity (O.D.) was greater than the mean (plus 2 standard devia-
ions) O.D. values observed for naïve mouse sera assayed against
oth DS and DK AMA-1 at 1/100.
.3. Parasite challenge and monitoring of within-host dynamics
Two weeks after the boost immunization, groups of immu-
ized mice (18 per group) were further randomized into groups
f six and challenged with 105 parasites of either clone DS alone,
lone DK alone or a mixture of clone DS and DK (Table 1).
hus, mice infected with both clones received twice as many
arasites as those infected with one clone. A two-fold differ-
nce in infective dose has negligible effects on the population
ynamics of the parasite [58a]. During the course of infection,
e measured body weights and took blood samples from the
ail to (i) make Giemsa-stained blood smears, (ii) estimate red
lood cell density by ﬂow cytometry (Beckman Coulter), and (iii)
or genotype-speciﬁc real-time quantitative PCR (qPCR) assays as
escribed previously [59]. For ampliﬁcation of the DK genotype,
e used primers previously designed to amplify AS/AJ genotypes
s described elsewhere [59]. DS genotype-speciﬁc primers were as
ollows: DS forward 5′-GGA AAA GGT ATA ACT AAT CAA AAA TCT
h
i
I
e
aal mix of both forms of AMA-1 (bi-allelic), or immunization with adjuvant only
nts before being separated into groups of 6. Infection was with parasites of clone
dead and 3 had to been euthanized due to severe morbidity. Euthanization was at
CT AAA-3′; DS reverse 5′-CAG GAG AAA TGT TTA CAT CTG CTT
-3′.
.4. Trait deﬁnition and statistical analyses
Since P. chabaudi has a 24-h replication cycle, the total number
f parasites present in any period can be estimated by summing
he daily parasite counts. Data were analysed using General Linear
odels (GLMs) in MINITAB. To meet normality and homogene-
ty of variance assumptions, data on antibodies, weight and red
lood cell density were log transformed while all parasite den-
ities and proportions were square root transformed. GLMs were
sed to test whether the magnitude of protection differed between
he three antigen immunizations (DK AMA-1, DS AMA-1, or the
i-allelic form); that is whether there was a statistical interac-
ion between infecting clone and immunizing treatments.Maximal
odels (response variable = infecting clone+ immunizing treat-
ent + infecting clone× immunization treatment) were tested in
he ﬁrst instance, and minimal models were obtained by drop-
ing non-signiﬁcant terms successively, beginning with highest
rder interactions, to obtain the signiﬁcant minimal model. For
nalyses of within-host selection, we asked for mixed clone infec-
ions, whether the frequency of clone DS in the parasite population
iffered between the sham-immunized controls and the antigen
mmunizations.
. Results
Table 1 gives details of the immunization treatments, infecting
lone and sample size of the experiment. Some mice died; these
ere included in thecalculationofdailydensitiesuntil death, and in
he analyses of peak parasite densities since death always occurred
s initial parasiteamias were declining.
.1. Pre-challenge anti-AMA-1 IgG2b antibodies
Fig. 1 illustrates the data from a pilot experiment where IgG2b
ntigen-speciﬁc antibodies were measured to each of the immu-
izing antigens and the cross-reactivity between them. All antigen
mmunization treatments generated antibody titres that were
igher than those present in sham-immunized controls (sham-
mmunized versus antigen immunized: F1,62 = 8.92, p=0.004).
gG2b antibodies were speciﬁc for the antigen they had been
xposed to during immunization (immunizing treatment×ELISA
ntigen: F1,40 = 9.99, p=0.003). For example, anti-DS AMA-1 IgG2b
6102 V.C. Barclay et al. / Vaccine 2
Fig. 1. IGg2b antibody levels from the serum of mice in the pilot experiment. Mice
were either sham-immunized or immunisedwith one of the two atingens (DS AMA-
1, DK AMA-1). Each of the treatments used to immunize mice and the AMA-1 test
antigen used to coat ELISA plates are shown on the x-axis. Dots represent the anti-
body titre against a particular immunizing antigen for a single mouse. Horizontal
lines indicate mean antibody levels. Antibody levels in antigen immunized groups
of mice were higher than in sham-immunized controls (p<0.001) and, among the
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ammunized mice, the levels induced between the antigen immunized groups dif-
ered (immunizing treatment×ELISA antigen: p=0.003) with higher titres against
he homologous antigen. Neither of the immunising antigens induced higher titres
p>0.05).
ntibody tires were higher when assayed against the homologous
S antigen than the heterologous DK antigen and vice versa. Thus,
either antigen elicited a stronger response overall.
Fig. 2 illustrates the IgG2b antibody titres in mice from the main
xperiment 3 days prior to parasite infection. All antigen immu-
ization treatments induced antibody titres that were higher than
hose present in sham-immunized mice (sham-immunized versus
mmunized: F1,106 = 58.89, p<0.001). Among antigen-immunized
roups, titres did not differ (F2,69 = 2.56, p=0.085). In those mice
hich had been immunized with the bi-allelic form, antibodies
ere not more speciﬁcally recognising either component antigen
F1,35 = 0.61, p=0.44). These data show that immunization success-
ully elicited antibody responses, and that, at least as measured by
gG2b titres, these responses were of equal magnitude in all immu-
ig. 2. IgG2b antibody levels from the serum of mice in the main experiment. Mice
ere either sham-immunized, or immunized with one of the antigen immuniza-
ion treatments (DS AMA-1, DK AMA-1 or the bi-allelic formulation). Each of the
reatments used to immunize mice and the AMA-1 test antigen used to coat ELISA
lates are shown on the x-axis. Dots represent the antibody titre for individual mice
gainst a particular antigen. Mice that were sham-immunized or immunized with
he bi-allelic formulation were assayed for antibody responses against both DS and
K AMA-1 antigens. Horizontal lines indicate mean antibody levels. Antibody levels
nantigen immunizedgroupsofmicewerehigher than in sham-immunized controls
p<0.001), and among the antigen immunized mice, antibody titres did not differ
p=0.085). The antibody titres in animals immunized with both antigens were not
ominated by responses to either one (p=0.44).
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ized groups. Among antigen-immunized mice, antibody titres
rior to challenge did not predict subsequent parasite intensities,
eight loss or anaemia (all correlations, p>0.2).
.2. Bi-allelic immunization did not generate a greater
nti-morbidity response than did mono-allelic immunization
Red blood cell density and weight kinetics following parasite
hallenge for each of the immunization treatments are illustrated
n Fig. 3A–F, and theminimum red blood cell density andminimum
eight reached are illustrated in Fig. 3G–H. In sham-immunized
ontrol mice, clone DK was less virulent than clone DS, induced
ess anaemia and less weight loss (Fig. 3A–H; anaemia: F2,14 = 6.29,
= 0.011; weight loss: F2,14 = 9.97, p=0.002).
Immunization protected mice against anaemia induced by
nfection with any of the clones (Fig. 3A–C, G; sham-immunized
ersus immunized: F1,69 = 16.94, p<0.001). Bi-allelic immunization
educed anaemia no more than did immunization with either of
he alleles alone (Fig. 3G; immunizing treatment× infecting clone:
4,44 = 0.71, p=0.59). All pairwise immunization comparisons were
on-signiﬁcant (p>0.5 in all cases).
As infection with clone DK did not induce any weight loss in
ham-immunized controls (Fig. 3D) the protective effects of immu-
ization were analysed only for infections that contained clone DS
Fig. 3E–F).We found that all immunizationsprotectedmice against
eight loss due to DS infections (Fig. 3E–F, H; sham-immunized
ersus immunized: F1,45 = 11.13, p=0.002). Similar to the anaemia
ata, we found that immunization with either the bi-allelic form
r either of the alleles alone afforded similar levels of protec-
ion againstweight loss (Fig. 3H; immunizing treatment× infecting
lone: F2,29 = 2.43,p=0.11). All pairwise immunization comparisons
ere non-signiﬁcant (p>0.5 in all cases).
Together, these results show that immunization with the bi-
llelic vaccine does not afford the host greater protection from
orbidity, as measured by anaemia and weight loss. Immuniza-
ion with either of the variants alone provided protection which
as as effective as that induced by the two variants together.
.3. Bi-allelic immunization did not generate greater
nti-parasite response than did mono-allelic immunization
Parasite dynamics under each of the treatments are illus-
rated in Fig. 4. Clone DS achieved higher parasite density in
ham-immunized control mice than did clone DK (infecting clone:
1,10 = 7.03=0.024).
All three immunizations reduced peak parasite densities rel-
tive to those which had received a sham inoculation (Fig. 4D;
ham-immunized versus immunized: F1,69 = 11.55, p=0.001). The
xtent of anti-parasite protection depended on the identity of the
mmunising antigenand the identity of the challenge clone (Fig. 4D;
mmunizing treatment× infecting clone: F4,44 = 8.71, p<0.001). We
ound that protection was clone-speciﬁc: immunization with DS
MA-1 antigen reduced DS parasite densities more than it reduced
he densities of clone DK, and vice versa (among single anti-
en immunized groups, immunizing treatment× infecting clone:
1,19 = 36.26, p<0.001).
When we compared the extent of anti-parasite protection
etween the immunized groups we found that under no circum-
tances did the bi-allelic immunization afford greater protection
han did immunization with a single allele. For example, immu-
ization with DS AMA-1 reduced the peak density of DK infections
nd infections with both clones together, but the bi-allelic
mmunization did not protect against DS alone (Fig. 4D; immu-
izing treatment× infecting clone: F2,30 = 9.84, p=0.001). Although
he bi-allelic immunization reduced the densities of clone DK,
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Fig. 3. Effect of Plasmodium chabaudi infection (clone DK alone, DS alone or DS+DK) and immunization (sham-immunized control, DK AMA-1, DS AMA-1, or bi-allelic form)
on the kinetics of minimum red blood cell density (left panels) and minimum weight (right panels). In A–F lines represent the change in RBC density (left panels) and weight
(right panels) over time. Each line represents the mean of up to 6 mice (±1S.E.M.) that were infected with DK alone (A and D), DS alone (B and E) or a mixed clone (C and F)
infection during immunization with either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle), DS AMA-1 (open squares), or the bi-allelic mixture
(dotted black line). In G–H bars represent the minimum red blood cell density (left panel) and minimum weight (right panel) reached during infection with clone DK alone
(grey bars), DS alone (black bars) or a mixture of both clones (black and white bars) under each of the immunization treatments. Each bar represents the least squares mean
of up to 6 mice (±1S.E.M.).
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Fig. 4. Kinetics of P. chabaudi infections (clones DK alone, DS alone or both together)
following immunization (DK AMA-1, DS AMA-1, or bi-allelic formulation or sham-
immunized control). In A–C, lines represent the change in parasite density over time.
Each line represents the mean of up to 6 mice (±1S.E.M.) that were infected with
DK alone (A), DS alone (B) or a mixed clone (C) infection during immunization with
either a sham-inoculation control (solid thick black line), DK AMA-1 (open triangle),
DS AMA-1 (open squares), or the bi-allelic mixture (dotted black line). In (D), bars
represent peakparasite densities reachedduring infectionwith cloneDKalone (grey
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Fig. 5. Proportion of clone DS in mixed DS and DK infections following immuniza-
tion with DK AMA-1, DS AMA-1, the bi-allelic formulation, or in sham-immunized
controls. (A) Lines represents the proportion of clone DS through time in control
(solid black line), DK AMA-1 (open triangles), DS AMA-1 (open diamonds) or bi-
allelic (dotted black line) immunized mice. Each line represents the mean of up
to 6 mice (±1S.E.M.). (B) Bar graphs represent the proportion of total parasites in
a mixed infection that were DS under each of the immunization treatments. Each
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nder each of the immunization treatments. Each bar represents the least squares
ean of up to 6 mice (±1S.E.M.).
eduction was no greater than with a single DK AMA-1 immuniza-
ion (Fig. 4D; immunizing treatment× infecting clone F =4.09,2,29
= 0.027).
Together these results show that bi-allelic immunization did
ot afford the host greater anti-parasite protection than did
ono-allelic immunization. Unlike morbidity, where protection
t
T
l
uar represents the least squares mean of up to 6 mice with 95% conﬁdence inter-
als. The black horizontal dotted line represents the proportion DS present in the
noculum.
as induced regardless of the antigen used in immunization,
e found that immunization with a single allele achieved better
rotection against the homologous clone, and bi-allelic immu-
ization never did as well. Indeed, we found just one of the
ariants (DS AMA-1) to be the most effective at reducing parasite
ensities.
.4. Vaccine-induced anti-parasite protection was clone speciﬁc
n mixed infections and independent of clone virulence
To examine how the antigenic composition of the immuniz-
ng formulation affects within-host selection (relative frequency)
n mixed clone infections, and whether heterologous immunity
ess effectively controlled the virulent clone, we compared the fre-
uency of clone DS in mixed infections (Fig. 5).
We found that antigen immunization altered clone frequen-
ies. In sham-immunized mice, and those immunized with the
i-allelic formulation, DS made up about 60% of all the parasites
resent in the infections. Thus, immunization with a mixture of DS
nd DK AMA-1 had negligible effect on clone frequency and thus
ithin-host selection (Fig. 5A; sham-immunized versus bi-allelic
mmunization: F1,10 = 2.02, p=0.19). In contrast, immunizationwith
single antigen reduced parasites in a clone-speciﬁcmanner, facili-
ating the heterologous clone (Fig. 5A andB; immunizing treatment
1,10 = 105.54, p<0.001). Immunization with DK AMA-1 increased
he frequencyof cloneDS,whileDSAMA-1 immunization increased
he frequency of DK. These effects were essentially symmetrical.
hus, there was no evidence that the more virulent clone, DS, was
ess affected by heterologous immunization than was the less vir-
lent clone DK.
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. Discussion
In this study, we investigated (i) whether immunization with
single or bi-allelic AMA-1 formulation afforded the host the
reatest protection from morbidity and parasite infection, (ii) how
hese different vaccination regimes altered clonal compositions in
ixed infections, and (iii) whether a more virulent clone was less
uccessfully controlled by vaccine-induced protective responses.
ddressing each of these in turn, we found the following. (i)
i-allelic immunization did not generate better anti-morbidity
r anti-parasite protection than did single allele immunization.
ather, immunization with one of the two variants alone (DS) pro-
ided the best protection. (ii) Both single variant immunizations
educed the frequency of homologous clones in mixed infections;
i-allelic immunization had no impact on within-host selection.
iii) There was no evidence that the more virulent clone (DS) was
etter at evading vaccine-induced immunity than was the less vir-
lent clone.
Rightly, protecting individual hosts from morbidity is one of
he goals of malaria vaccines directed against the blood-stage of
nfection. If infection densities are positively correlated with host
orbidity (virulence) [27] multi-allele vaccines could potentially
mprove the health of the host by suppressing more of the parasite
opulation and reducing strain-speciﬁc responses. Subject to the
sual cautions about generalising from animal models (reviewed
n this context by Råberg et al. and Wargo et al. [60,61]), the
esults presented here argue against that, and suggest that protec-
ive efﬁcacy may not be increased by including alternative variants
f AMA-1. Our in vivo observations are consistent with previous
esults showing that immunization of rhesus monkeys with only
ne of two PfAMA-1 variants is sufﬁcient to induce cross-protective
ntibody responses as measured by GIA and ELISA assays in vitro
52]. Our results are also consistent with another study which
emonstrated that mice and rabbits immunized with two allelic
ariants of domain I and II of the full length AMA-1 ectodomain
rom Indian P. falciparum isolates were able to inhibit in vitro para-
ite growth, but to no greater extent than with either of the allelic
ariants alone [53].
Our results also demonstrate strain-speciﬁc anti-parasite
esponses (Fig. 4D) need not result in strain-speciﬁc protection
gainst disease (Fig. 3G and H). The observation that there are two
ifferent types of anti-malarial responses – immunity against the
arasite itself and immunity against disease – is poorly understood
n a molecular basis although the distinction is widely appreci-
ted [62]. An explanation for the two different responses observed
ere could be that the speciﬁcity of the anti-AMA-1 antibody
esponse lies with the generation of inhibitory antibodies which
ay target the hypervariable region located around a conserved
ydrophobic pocket on domain I [63]. The presence of such anti-
odies could determine the observed parasitaemias. For bi-allelic
mmunizations there may exist a dominant epitope in one allelic
orm of AMA-1. Thus, high titres of cross-reactive antibodies may
e sufﬁcient to lessen morbidity (hence the similar effects for
ono-and-bi-allelic vaccination on morbidity) but the inhibitory
ntibodies are more effective at controlling parasite numbers by
nhibiting invasion. In our pilot studies we did not observe a dis-
roportional IgG2b antibody response to one of the immunizing
ntigens (Fig. 1).However, since immunizationwithAMA-1 is likely
o induce a repertoire of IgG isotypes [58a,64–66] some of the
ther isotypes may be sufﬁciently cross-reactive. An implication
f this may be that while strain-speciﬁc immunization may alter
llele frequencies in parasite populations, this need not have clini-
al consequences in a vaccinated host. Changes in allele frequencies
ithout public health consequences have been seen in some other
iseases, such as pertussis (reviewed in [26]).
n
v
t
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The ‘CombinationB’malaria vaccine, oneof the fewto reachﬁeld
rials, demonstrated strain-speciﬁc anti-parasite effects despite
eing comprised of an allele of each of 3 asexual blood stage pro-
eins, MSP-1, MSP-2 and RESA (ring-infected erythrocyte surface
ntigen) [29]. Of particular interest was that vaccination increased
he frequency of parasiteswith anMSP-2 genotypebelonging to the
C27 allelic family. No representatives of this allelic family, which
ad been found previously to be associated with severe morbid-
ty, were included in the vaccine [16,29,30]. Selection for the FC27
orm of MSP-2 could have been because of strain-speciﬁc protec-
ion [15,31], or because the vaccine was less effective at protecting
gainst more virulent strains [26–28]. In the study we report here,
e looked at the relative proportion of the more virulent clone
n a mixed infection under the different immunization composi-
ions. In sham-immunized control mice and those which received
he bi-allelic immunization, the more virulent clone (DS) was pro-
ortionally the most dominant. Thus, bi-allelic immunization did
ot alter within-host selection. On the other hand, immunization
ith a single AMA-1 variant did facilitate evasion of the heterolo-
ous clone in mixed infections. In our experiments, this effect was
ymmetrical (Fig. 5), so that immunization with AMA-1 appears to
nduce protective responses that are strain-speciﬁc and evasion is
ndependent of parasite virulence.
Nevertheless, selection for virulence could be an inadvertent
onsequence of including just one allele from a given locus in a
accine, as apparently happened in the Combination B trial. As far
s we are aware, there are no reports that variants of AMA-1 have
ifferent intrinsic virulence, so that the strain-speciﬁc immunity
gainst this locus we report here and that has been seen by others
7,34], should not directly alter virulence. But caution is necessary
or all antigens involved in processes like cell invasion which are
ssociated with pathogenesis. Population-level association studies
or disease severity should be performed for all antigens included
n candidate vaccines. Should associations like that for MSP-2 be
ound [30], we suggest on the basis of our results that there would
e a strong case for including all known variants at that locus in the
accine. This would not confer short-term clinical advantage, but it
ould be the safest way to avoid inadvertent selection for virulent
ariants, which would put unvaccinated people at greater risk.
More generally, though, we still have some way to go to under-
tand the potential for vaccine-driven virulence evolution, even in
he P. chabaudi model. One experimental study demonstrated that
arasites from a single P. chabaudi clone serially passaged through
hole-parasite immunized mice evolved to be more virulent than
hose evolved in naive hosts [28]. That study was the ﬁrst to show
nder controlled conditions that immunization can favour the evo-
ution of more virulent parasites. The implication was that more
irulent variants had a selective advantage in immunized hosts. In
he study we report here, which did not involve serial passage, we
aw no signs of such an advantage. DS, the more virulent clone,
ominated in mice immunized with the bi-allelic form, but to the
ame extent as in non-immunized mice. In single antigen immu-
ized mice, strain-speciﬁc immunity dominated with symmetrical
ffects for both clones. Competition experiments with other P.
habaudi clones also failed to ﬁnd an increased advantage to vir-
lence in immunized hosts [67]. It may be that the accelerated
volution of virulence seen during serial passage in immunized
osts [28,68] is a feature of selection of virulence variants on an
ntigenically identical background. In future experiments, we will
erially passage single P. chabaudi clones through AMA-1 immu-
ized and naïve mice to determine whether vaccination can evolve
irulence to be greater when measured in naïve hosts.
Our experiments concerned antigenic polymorphism at a single
arget antigen. Considerably more work has focused on vaccines
ombining single variants frommultiple antigenic loci [1,69,70]. For
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xample, animal and human phase I trails have shown safety, toler-
bility and immunogenecity of formulations containingAMA-1 and
SP-1 [1,71–73]. Moreover, such ‘multi-valent’ vaccines have been
hown to reduce parasitaemias in mice of distinct MHC haplotypes
74] and against infections with different parasite strains as well
s subspecies of different virulence [75]. Thus, multi-valency may
e required to induce antibody responses against a repertoire of
olymorphic parasite antigens [64,66,76–81] in thehumanoutbred
opulation exposed to multiple parasite genotypes [29,78,82–84].
e suspect that multi-valent vaccines will prove to be a more efﬁ-
ient means of generating protection against the widest range of
arasite genotypes. Certainly, we found no evidence that the anti-
orbidity and anti-parasitic potency of a malaria vaccine would
e enhanced by increasing the number of variants of a particular
ntigen.
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